At today's price, IBM's stock is pricing in just 4.4% annual free-cash-flow growth for the next ten years — far below its actual FCF growth of 14.7% a year over the past two years. Measured against 5-year revenue growth alone (4.2% a year, a cleaner yardstick unaffected by a distorted FCF base year), the market's ask looks almost exactly in line instead.
At its current price, IBM implies ~4.4% annual FCF growth for the next 10 years, discounted at 9%.
IBM's actual FCF growth has averaged 14.7% a year over the past 2 years — more than 3 times what the current price requires.
Required growth vs. historical growth
Required growth from the reverse DCF below. FCF CAGRs from IBM's own reported figures; the 5-year figure is unusually high because 2021 (the base year) was depressed by one-time costs from the 2021 Kyndryl spinoff. Revenue CAGR is shown as a cleaner comparison, since it isn't affected by that base-year distortion.
Sensitivity: what if the discount rate moves?
| WACC | Required growth |
|---|---|
| 7% | -0.3% |
| 9% (base case) | 4.4% |
| 11% | 8.3% |
At a 7% discount rate, the required growth rate actually turns negative — meaning FCF wouldn't need to grow at all, and could even shrink slightly, to justify today's price. Even at the higher end tested (11%), the required rate (8.3%) still sits well below IBM's actual 2-year FCF pace.
What would move this number
- Using the 3-year average FCF ($12,894M) instead of FY2025's figure ($14,734M) as the base would raise the required growth rate somewhat, since a smaller starting point needs faster growth to reach the same target value.
- A 7% discount rate — arguably reasonable given IBM's investment-grade credit profile and 30-year dividend-increase streak — pushes the required growth rate into negative territory, an unusually low bar for any reverse DCF on this site.
- The 5-year FCF comparison (22.7%) is distorted by a weak 2021 base right after the Kyndryl spinoff; the 2-year comparison (14.7%) and revenue growth (4.2%) are both cleaner reads, and they tell two different stories — one still comfortably above the market's ask, one nearly matching it exactly.
Show your work
Inputs, sources, model assumptions, and the calculation
- Share price$233.87 — stockanalysis.com, Aug 31, 2026 close
- Diluted shares outstanding942.13M
- Market cap$220,336M — price × diluted shares (calculated)
- Base FCF (FY2025)$14,734M — IBM's own reported figure (see the snapshot piece for a caveat on IBM's self-defined FCF)
- Total debt (FY2025 year-end)$61,260M
- Cash & marketable securities (FY2025 year-end)$14,470M
- Net debt$46,790M — calculated
- Discount rate (WACC)9% base case (7%/11% tested)
- Terminal growth rate2.5% — long-run GDP-level assumption
Normalization check: 3-year average FCF (2023-2025) is $12,894M; FY2025's figure ($14,734M) is +14.3% above that average — within the ±40% threshold, so used as-is without adjustment.
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value (market cap plus net debt, $267,126M).
Historical CAGR check: 2-yr FCF CAGR (2023→2025) = ($14,734M ÷ $11,200M)^(1/2) − 1 = 14.7%. 5-yr FCF CAGR (2021→2025) = ($14,734M ÷ $6,508M)^(1/4) − 1 = 22.7%. 5-yr revenue CAGR = ($67,535M ÷ $57,350M)^(1/4) − 1 = 4.2%.
The fine print
- This isn't a fair-value price target — it only shows what the current price already assumes.
- IBM's self-reported FCF doesn't exactly match a simple "operating cash flow minus capex" calculation (2025: $13.2B operating cash flow, $1.6B capex, yet reported FCF is $14.7B) — the additional adjustments IBM applies aren't fully itemized in the materials reviewed for this analysis.
- Change the discount rate or the FCF base, and the answer moves substantially — see the sensitivity table above.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Any investment decision, and its outcome, is your own responsibility.
Frequently asked questions
What growth rate does IBM's stock price assume?
At today's price, IBM's stock is pricing in about 4.4% annual free-cash-flow growth for the next ten years, at a 9% discount rate.
How does that compare to IBM's actual growth?
IBM's FCF grew 14.7% a year over the past 2 years and 22.7% over the past 5 (though the 5-year figure is inflated by a weak 2021 base right after the Kyndryl spinoff). Revenue itself grew just 4.2% a year over 5 years — almost exactly matching the market's 4.4% ask.
What share price was used for this analysis?
This analysis used $233.87, as of the Aug 31, 2026 close.